## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

No thesis match: PEG 1.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($472.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. United Therapeutics stock hits all-time high at 492.62 USD**
- Source: Investing.com | 20251212T150919 | Bullish | Relevance: 100%
- United Therapeutics stock (UTHR) reached an all-time high of $492.62, marking a 35.66% increase over the past year and reflecting strong investor confidence despite recent revenue shortfalls. While the company's third-quarter revenue and Tyvaso franchise missed analyst expectations, Jefferies and TD Cowen reiterated Buy ratings with increased price targets, signaling an optimistic outlook for future growth. Management projects quarterly revenue to hit approximately $1 billion by late 2027.

**2. Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T130907 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.2% in the second quarter, valuing its holdings at approximately $14.77 million. This comes despite recent insider selling by executives. Analysts maintain a "Moderate Buy" rating for United Therapeutics with an average price target of $505.00, reflecting confidence in the biotechnology company's performance and future prospects.

**3. Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T120907 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans recently reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8%, now holding 185,477 shares valued at $53.30 million. Insider selling has also been noted, with CEO Martine Rothblatt selling shares, though institutional investors still hold a significant portion of the company. United Therapeutics reported Q3 EPS of $7.16, exceeding estimates, and has a "Moderate Buy" consensus rating with a $505 price target.

**4. Globeflex Capital L P Grows Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251212T190922 | Bullish | Relevance: 100%
- Globeflex Capital L P increased its stake in United Therapeutics Corporation by 6.7% in Q2, bringing its total to 58,516 shares, and institutional investors now collectively own about 94.08% of the company. Several analysts have raised their target prices for UTHR, contributing to a "Moderate Buy" consensus and a $505 target. Despite missing revenue estimates, the company beat EPS expectations, and the stock is trading near its 52-week high with a market cap of approximately $21 billion.

**5. Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor**
- Source: GuruFocus | 20251210T000921 | Somewhat-Bearish | Relevance: 100%
- United Therapeutics Corp Director Nilda Mesa sold 187 shares of the company on December 9, 2025, reducing her holdings to 5,286 shares. The company has seen 103 insider sells and no insider buys in the past year. United Therapeutics Corp is considered modestly overvalued with a price-to-GF-Value ratio of 1.28.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 26 ($19.96M) |
| Sells | 62 ($23.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $23M sold (62 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +5.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.3x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.3B |
| Beta | 0.86 |
| 52W Range | $266.98 - $496.73 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.3 |
| Current P/E | 18.2 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.6% to 3.5% (+5.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 70th percentile. MRS_5 at 3.3% confirms short-term momentum alignment. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.70), momentum weakening. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.49% (CS: 71) | Strong |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.70 | Bearish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.398x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $493.99
- **Stop Loss:** $472.23 (4.4% risk)
- **Target:** $515.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 45
- **Position Value:** $22,229.55
- **Portfolio %:** 22.23%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*